Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib plus dexamethasone for adult primary hemophagocytic syndrome (Phase II, single-arm)
ChiCTR2100049996Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in haemophagocytic lymphohistiocytosis (HLH), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Overall survival at 60 days. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on ChiCTR2100049996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049996.